What's in Gamida Cell ltd's pipeline?

Gamida Cell ltd has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Gamida Cell ltd's portfolio?

Top competitors by shared drug class: Aivita Biomedical, Inc., Bone Therapeutics S.A, Capricor Inc., University of Missouri-Columbia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gamida-cell-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Gamida Cell ltd — Portfolio Competitive Intelligence Brief

Gamida Cell ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NiCord® (omidubicel)	NiCord® (omidubicel)	phase 3	Allogeneic cell therapy		Hematology/Oncology

Therapeutic area mix

Hematology/Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aivita Biomedical, Inc. · 1 shared drug class
Bone Therapeutics S.A · 1 shared drug class
Capricor Inc. · 1 shared drug class
University of Missouri-Columbia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gamida Cell ltd:

Cite this brief

Drug Landscape (2026). Gamida Cell ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gamida-cell-ltd. Accessed 2026-05-14.